Regeneron Pharmaceuticals Inc. buy Wells Fargo & Company
Summary
This prediction ended on 24.09.25 with a price of €480.00. Massive losses of -51.79% were the result for the BUY prediction by Wells_Fargo___Compan. Wells_Fargo___Compan has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. A total of €2.60 was paid as dividends for this prediction. Wells_Fargo___Compan has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 1.137% | 1.137% | -3.348% |
| iShares Core DAX® | 2.331% | 5.140% | 25.000% |
| iShares Nasdaq 100 | 2.077% | 2.956% | 8.935% |
| iShares Nikkei 225® | 2.759% | 7.214% | 22.171% |
| iShares S&P 500 | 1.613% | 2.893% | 6.249% |
Comments by Wells_Fargo___Compan for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Wells_Fargo___Compan for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
30.04.25
30.04.26
12.01.26
Stopped prediction by Wells_Fargo___Compan for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
10.01.25
10.01.26
11.01.26
Regeneron Pharmaceuticals Inc.
02.08.24
02.08.25
03.08.25

